Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
Each year, Connecticut Magazine recognizes some of the state’s best physicians, who provide exceptional care for patients, with its annual “Top Doctors” issue. This year’s list includes 82 physicians from Smilow Cancer Hospital and Yale Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in the state.
Warning Signs of Oral Cancer
Do you know the warning signs of oral cancer? Some oral cancer symptoms are common and easily identifiable. Other symptoms are surprising, and you might miss them. Here, experts break down the symptoms of oral cancer you should be aware of, plus how to prevent oral cancer.Source: HealthDay
Yale researchers to present new data on novel treatment for drug-resistant brain cancers at AACR Meeting
A research team led by Yale Cancer Center members Seth Herzon, PhD, and Ranjit Bindra, MD, PhD, developed new molecules that exploit a specific DNA-repair defect in these brain cancers to achieve tumor-specific cell killing.
Yale Cancer Center Experts to Present New Research at Annual AACR Meeting
Yale Cancer Center and Smilow Cancer Hospital physicians and scientists are presenting research studies at the 2023 American Association for Cancer Research (AACR) Annual Meeting at the Orange County Convention Center in Orlando, Florida, April 14 to 19. Research teams will reveal the latest data on treatments and diagnostic advances as well as new findings on head and neck, lung, and metastatic cancers.
New Findings Support Novel Combination Treatment for Head and Neck Cancers
Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) and lung cancer can have disruptive mutations in TP53and/or CDKN2A tumor suppressor genes, which are associated with poor patient survival. Division Chief of Heck and Neck Cancers/Sarcoma at Yale Cancer Center and Smilow Cancer Hospital, Barbara Burtness, MD, will join fellow researchers to share new findings, building on a study published in Clinical Cancer Research at the April American Association for Cancer Research (AACR) annual meeting in Orlando, FL. Dr. Burtness is co-author of the study, which suggested a combination treatment with adavosertib and alisertib led to antitumor effects.
Looking for Silver Linings After Conquering Cancer, Wilton’s Donna Savage Aims to Help Others
The formidable experience of contracting oropharyngeal cancer brought life-changing tribulations to Donna Savage, but unexpected opportunities to share her experience and hope with others have likewise provided some “silver linings” in her life.Source: Good Morning Wilton
How Black Americans Diagnosed With Head and Neck Cancer Can Get the Best Treatment
Researchers continue to examine healthcare disparities and genetics to better understand why Black patients diagnosed with head and neck cancer experience higher mortality rates and are at more advanced stages of the disease at the time of diagnosis than whites.Source: Everyday Health Logo
Yale Cancer Center Presents Awards for Excellence in Clinical Care
The Yale Cancer Center Awards for Excellence in Clinical Care were presented by Kevin Billingsley, MD, MBA, FACS, to two outstanding physicians at Smilow Cancer Hospital: Manju Prasad, MD, MBBS, Professor of Pathology and Director of the Head & Neck and Endocrine Pathology Program and Saral Mehra, MD, MBA, FACS, Associate Professor of Surgery (Otolaryngology) and Section Chief, Head and Neck Surgery at the annual Yale Cancer Center Conclave on January 5, 2023.
Barbara Burtness, MD, Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.
Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC
Aarti Bhatia, MD, discusses the rationale for investigating berzosertib in this patient population, key updates from the phase 1 trial, and how these findings support the need for continued research of novel regimens in HNSCC.Source: OncLive
Press Release: Head and Neck Cancer Researchers Demonstrate the Capability of a Deep Learning Algorithm in the Post-Surgery Setting to Assess the Stage of Disease More Accurately Using Standard CT Scans
In a cohort of newly diagnosed patients in the E3311 trial at high risk for recurrence by standard assessment, a neural network algorithm demonstrated superior accuracy in measuring the extent of cancer spread, outperforming expert radiologistsSource: Ecog-Acrin
Judson Appointed Charles W. Ohse Professor of Surgery (Otolaryngology)
Benjamin Judson, MD, MBA, whose research interests include investigating outcomes and quality in head and neck cancer therapy, has been appointed Charles W. Ohse Professor of Surgery (Otolaryngology) at Yale School of Medicine, effective immediately.Source: YaleNews
Yale Doc: Throat, Neck Cancers Caused by HPV ‘Completely Preventable’ with Caccine
While cancer of the throat, back of the tongue, tonsils and soft palate (the location of the uvula), known as oropharyngeal cancer, can be caused by smoking or heavy drinking, HPV also has been linked to it, according to Dr. Saral Mehra, section chief for head and neck and otolaryngology surgery at the Yale School of Medicine.Source: CT Insider
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss
Oropharyngeal squamous cell carcinoma (OPSCC) accounts for over half of all head and neck cancers. Since the 1970s, OPSCC has shifted from an environmentally triggered to virally mediated disease due to a sharp rise in human papillomavirus (HPV)-related SCC.Source: National Library of Medicine